» Articles » PMID: 8359187

Plasma Protein Binding of the Enantiomers of Hydroxychloroquine and Metabolites

Overview
Specialty Pharmacology
Date 1993 Jan 1
PMID 8359187
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The in vitro binding of the enantiomers of hydroxychloroquine and its three major metabolites in pooled plasma obtained from four healthy volunteers and the binding of the enantiomers of hydroxychloroquine to purified plasma proteins has been investigated. The plasma protein binding of hydroxychloroquine was found to be stereoselective. The (S)-enantiomer of hydroxychloroquine was 64% bound in plasma, while (R)-hydroxychloroquine was 37% bound. Fifty% of (S)-hydroxychloroquine was bound to a 40 g.l-1 solution of human serum albumin, while only 29% of the (R)-enantiomer was bound. The enantioselectivity of hydroxychloroquine binding was reversed in a 0.7 g.l-1 solution of alpha 1-acid glycoprotein with (R)-hydroxychloroquine being bound to a greater extent than its optical antipode (41% versus 29%). The enantiomers of the metabolites of hydroxychloroquine were bound to a similar extent to plasma and purified plasma proteins. Binding of hydroxychloroquine to plasma and purified proteins was found to be linear over the racemic concentration range of 50 to 1000 ng.ml-1 and hydroxychloroquine metabolite binding to plasma was linear over the range 25 to 500 ng.ml-1.

Citing Articles

The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel.

Alsmadi M, Jaradat M, Obaidat R, Alnaief M, Tayyem R, Idkaidek N AAPS PharmSciTech. 2023; 24(6):172.

PMID: 37566183 DOI: 10.1208/s12249-023-02627-3.


Predicting Hydroxychloroquine Clearance in Healthy and Diseased Populations Using a Physiologically Based Pharmacokinetic Approach.

Alqahtani F, Asiri A, Zamir A, Rasool M, Alali A, Alsanea S Pharmaceutics. 2023; 15(4).

PMID: 37111735 PMC: 10140819. DOI: 10.3390/pharmaceutics15041250.


In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine.

Ballet V, Bohme G, Brohan E, Boukaiba R, Chambard J, Angouillant-Boniface O Eur J Pharmacol. 2021; 915:174670.

PMID: 34863995 PMC: 9749463. DOI: 10.1016/j.ejphar.2021.174670.


Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features.

Ferreira P, Ferreira J, de Sousa R, Bezerra D, Militao G J Oncol. 2021; 2021:3569349.

PMID: 34527050 PMC: 8437624. DOI: 10.1155/2021/3569349.


The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.

Das S, Ramachandran A, Birangal S, Akbar S, Ahmed B, Joseph A Med Drug Discov. 2021; 10:100085.

PMID: 33846702 PMC: 8026171. DOI: 10.1016/j.medidd.2021.100085.


References
1.
Skeith K, Jamali F . Clinical pharmacokinetics of drugs used in juvenile arthritis. Clin Pharmacokinet. 1991; 21(2):129-49. DOI: 10.2165/00003088-199121020-00004. View

2.
Tett S, Cutler D, Day R, Brown K . A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1988; 26(3):303-13. PMC: 1386543. DOI: 10.1111/j.1365-2125.1988.tb05281.x. View

3.
Ofori-Adjei D, Ericsson O, Lindstrom B, Sjoqvist F . Protein binding of chloroquine enantiomers and desethylchloroquine. Br J Clin Pharmacol. 1986; 22(3):356-8. PMC: 1401130. DOI: 10.1111/j.1365-2125.1986.tb02900.x. View

4.
Williams K, Lee E . Importance of drug enantiomers in clinical pharmacology. Drugs. 1985; 30(4):333-54. DOI: 10.2165/00003495-198530040-00003. View

5.
McLachlan A, Tett S, Cutler D . High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an alpha 1-acid glycoprotein stationary phase. J Chromatogr. 1991; 570(1):119-27. DOI: 10.1016/0378-4347(91)80206-r. View